Sugi Predict

Sugi Predict / Compounds / SCHEMBL24252754

SCHEMBL24252754

SCHEMBL24252754

COc1ccc(CNc2nnc(C)c3cc(B(O)O)ccc23)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.47
▸ APLNR P35414 1/20 0.44
▸ CYP1A2 P05177 14/20 0.43
▸ CYP3A4 P08684 14/20 0.43
▸ CYP2C19 P33261 14/20 0.43
▸ TSHR P16473 12/20 0.43
▸ CYP2D6 P10635 11/20 0.43
▸ HSD17B10 Q99714 8/20 0.43
▸ LMNA P02545 5/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ ALOX15 P16050 4/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CYP2C9 P11712 10/20 0.43
▸ ALDH1A1 P00352 9/20 0.43
▸ USP2 O75604 5/20 0.43
▸ MAPK1 P28482 5/20 0.43
▸ CLK4 Q9HAZ1 6/20 0.42
▸ HIF1A Q16665 4/20 0.42
▸ BCDIN3D Q7Z5W3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451931 0.89 CYP1A2 (0.53) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL24252777 0.89 CYP1A2 (0.53) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL30451850 0.89 CYP1A2 (0.45) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL24252314 0.89 CYP1A2 (0.45) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL30451934 0.88 CYP1A2 (0.45) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL24252825 0.88 CYP1A2 (0.45) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL29015444 0.87 MAPT (0.49) MAPTAPLNRCYP1A2CYP3A4CYP2C19
SCHEMBL24252412 0.86 CYP1A2 (0.53) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL24252878 0.86 CYP1A2 (0.46) MAPTCYP1A2CYP3A4CYP2C19TSHR
SCHEMBL30452727 0.86 CYP1A2 (0.46) MAPTCYP1A2CYP3A4CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 — — US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 — — US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 — — CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 — — CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 — — EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 MAPT 1152/4885APLNR 1122/4885CYP1A2 2977/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 MAPT 1152/4885APLNR 1122/4885CYP1A2 2977/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 MAPT 1152/4885APLNR 1122/4885CYP1A2 2977/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH MAPT 4803/4885APLNR 964/4885CYP1A2 4150/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 MAPT 4737/4885APLNR 490/4885CYP1A2 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.